Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Use of the Landmark Method
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to determine whether the use of drugs in the treatment of inflammatory bowel disease is related to the risk of colorectal cancer using a Cox proportional hazards model with the landmark method to minimize immortal time bias. Materials and Methods: This study was conducted as national cohort-based study using data from Korea’s Health Insurance Corporation. Newly diagnosed patients with inflammatory bowel disease from 2006 to 2010 were monitored for colorectal cancer until 2015. Hazard ratios and 95% confidence intervals were calculated and compared with the incidence of colorectal cancer with or without medications by applying various landmark points. Results: In patients with Crohn’s disease, the prevention of colorectal cancer in the group exposed to immunomodulators was significant in the basic Cox model; however, the effect was not statistically significant in the model using the landmark method. The preventive effect of 5-aminosalicylic acid in patients with ulcerative colitis was significant in the basic and 6-month landmark point application models, but not in the remaining landmark application models. Conclusion: In patients with inflammatory bowel disease, the preventive effect of drug exposure on colorectal cancer varies depending on the application of the landmark method. Hence, the possibility of immortal time bias should be considered.
Abstract
Purpose: This study aimed to determine whether the use of drugs in the treatment of inflammatory bowel disease is related to the risk of colorectal cancer using a Cox proportional hazards model with the landmark method to minimize immortal time bias. Materials and Methods: This study was conducted as national cohort-based study using data from Korea’s Health Insurance Corporation. Newly diagnosed patients with inflammatory bowel disease from 2006 to 2010 were monitored for colorectal cancer until 2015. Hazard ratios and 95% confidence intervals were calculated and compared with the incidence of colorectal cancer with or without medications by applying various landmark points. Results: In patients with Crohn’s disease, the prevention of colorectal cancer in the group exposed to immunomodulators was significant in the basic Cox model; however, the effect was not statistically significant in the model using the landmark method. The preventive effect of 5-aminosalicylic acid in patients with ulcerative colitis was significant in the basic and 6-month landmark point application models, but not in the remaining landmark application models. Conclusion: In patients with inflammatory bowel disease, the preventive effect of drug exposure on colorectal cancer varies depending on the application of the landmark method. Hence, the possibility of immortal time bias should be considered.
참고문헌 (34)
- Prada-Ramallal G, "Bias in pharmacoepidemiologic studies using secondary health care databases : a scoping review", BMC Med Res Methodol, 19, pp.53~ (2019)
- van Walraven C, "Administrative database research has unique characteristics that can risk biased results", J Clin Epidemiol, 65, pp.126~131 (2012)
- Weiss NS, "The new world of data linkages in clinical epidemiology: are we being brave or foolhardy?", Epidemiology, 22, pp.292~294 (2011)
- Rothman KJ, "Modern epidemiology" (1998), Lippincott-Raven
- Suissa S, "Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease : immortal time bias in observational studies", Am J Respir Crit Care Med, 168, pp.49~53 (2003)
- Suissa S, "Immortal time bias in observational studies of drug effects", Pharmacoepidemiol Drug Saf, 16, pp.241~249 (2007)
- Targownik LE, "Understanding and avoiding immortaltime bias in gastrointestinal observational research", Am J Gastroenterol, 110, pp.1647~1650 (2015)
- Suissa S, "Immortal time bias in pharmaco-epidemiology", Am J Epidemiol, 167, pp.492~499 (2008)
- Danese S, "Etiopathogenesis of inflammatory bowel diseases", World J Gastroenterol, 12, pp.4807~4812 (2006)
- Prideaux L, "Inflammatory bowel disease in Asia : a systematic review", J Gastroenterol Hepatol, 27, pp.1266~1280 (2012)
- Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)
- Bopanna S, "Risk of colorectal cancer in Asian patients with ulcerative colitis : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 2, pp.269~276 (2017)
- O’Connor PM, "Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease", Inflamm Bowel Dis, 16, pp.1411~1420 (2010)
- Farraye FA, "AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease", Gastroenterology, 138, pp.738~745 (2010)
- Cairns SR, "Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups(update from 2002)", Gut, 59, pp.666~689 (2010)
- Delaunoit T, "Colorectal cancer prognosis among patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 4, pp.335~342 (2006)
- Velayos FS, "Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk : a systematic review and metaanalysis of observational studies", Am J Gastroenterol, 100, pp.1345~1353 (2005)
- Connell WR, "Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease", Lancet, 343, pp.1249~1252 (1994)
- 하정은, "국내 염증성장질환의 약물치료 및 약제비 현황: 2010-2014 국민건강보험자료 활용 연구", 한국임상약학회지, 29(2), pp.79~88 (2019), 한국임상약학회[DOI]
- Nguyen GC, "5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease : a meta-analysis of non-referral populations", Am J Gastroenterol, 107, pp.1298~1304 (2012)
- Qiu X, "Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia : a systematic review with meta-analysis", Oncotarget, 8, pp.1031~1045 (2017)
- Ferraro S, "Is there a risk of lymphoma associated with anti-tumor necrosis factor drugs in patients with inflammatory bowel disease? A systematic review of observational studies", Front Pharmacol, 10, pp.247~ (2019)
- Eisenstein EL, "Clopidogrel use and long-term clinical outcomes after drugeluting stent implantation", JAMA, 297, pp.159~168 (2007)
- Lee CK, "Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database", J Gastroenterol Hepatol, 35, pp.760~768 (2020)
- Jung YS, "Cancer risk in the early stages of inflammatory bowel disease in Korean patients : a nationwide population-based study", J Crohns Colitis, 11, pp.954~962 (2017)
- Mi X, "Use of the landmark method to address immortal person-time bias in comparative effectiveness research : a simulation study", Stat Med, 35, pp.4824~4836 (2016)
- Gleiss A, "An unjustified benefit : immortal time bias in the analysis of time-dependent events", Transpl Int, 31, pp.125~130 (2018)
- Lewis JD, "Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn’s disease", Gut, 59, pp.1586~1587 (2010)
- Targownik LE, "Immortal time bias : a likely alternate explanation for the purported benefits of DXA screening in ulcerative colitis", Am J Gastroenterol, 109, pp.1689~ (2014)
- Christensen DM, "Protective association of angiotensin blockade with influenza: a result of immortal time bias?", Eur Heart J Cardiovasc Pharmacother, 7, pp.e58~9 (2021)
- Beigel F, "Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies", Pharmacoepidemiol Drug Saf, 23, pp.735~744 (2014)
- Airaksinen J, "An example of how immortal time bias can reverse the results of an observational study", Epidemiology, 31, pp.e19~20 (2020)
- Lévesque LE, "Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes", BMJ, 340, pp.b5087~ (2010)
- Park J, "Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database", Int J Arrhythm, 20, pp.5~ (2019)